116 related articles for article (PubMed ID: 9261544)
21. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
22. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA.
Rajan GP; Seifert B; Prümmer O; Joller-Jemelka HI; Burg G; Dummer R
Arch Dermatol Res; 1996 Aug; 288(9):543-8. PubMed ID: 8874750
[TBL] [Abstract][Full Text] [Related]
23. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.
Rönnblom LE; Alm GV; Oberg KE
Ann Intern Med; 1991 Aug; 115(3):178-83. PubMed ID: 2058872
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
[TBL] [Abstract][Full Text] [Related]
25. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a.
Itri LM; Sherman MI; Palleroni AV; Evans LM; Tran LL; Campion M; Chizzonite R
J Interferon Res; 1989 Sep; 9 Suppl 1():S9-15. PubMed ID: 2681444
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
[TBL] [Abstract][Full Text] [Related]
27. Minimal antigenicity of intron A in human recipients demonstrated by three analytical methods.
Jacobs SJ; Sullivan LM; Salfi M; Grossberg H; Spiegel RJ; Leibowitz PJ; Oden EM; Kelsey DK; Treuhaft MW
J Biol Response Mod; 1988 Oct; 7(5):447-56. PubMed ID: 3183684
[TBL] [Abstract][Full Text] [Related]
28. [Clinical significance of neutralizing anti-interferon antibodies in chronic hepatitis B patients treated with recombinant interferon-alpha].
Mao QG; Luo KX; Liu DL; Zhang MX; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2004 Apr; 12(4):205-7. PubMed ID: 15099466
[TBL] [Abstract][Full Text] [Related]
29. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
30. Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon.
Liao MJ; Axelrod HR; Kuchler M; Yip YK; Kirkbright E; Testa D
J Infect Dis; 1992 Apr; 165(4):757-60. PubMed ID: 1552208
[TBL] [Abstract][Full Text] [Related]
31. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection.
Lok AS; Lai CL; Leung EK
Hepatology; 1990 Dec; 12(6):1266-70. PubMed ID: 2258142
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of immune changes in patients with renal cancer and melanoma treated with interferon-alpha 2b.
Tsavaris N; Baxevanis K; Kosmidis P; Papamichael M
Tumour Biol; 1995; 16(6):365-73. PubMed ID: 7569683
[TBL] [Abstract][Full Text] [Related]
33. Antibodies in patients with recurrent respiratory papillomatosis treated with lymphoblastoid interferon.
Thurmond LM; Brand CM; Leventhal BG; Finter NB; Johnston JM
J Lab Clin Med; 1991 Sep; 118(3):232-40. PubMed ID: 1919296
[TBL] [Abstract][Full Text] [Related]
34. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
Pichert G; Jost LM; Fierz W; Stahel RA
Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
[TBL] [Abstract][Full Text] [Related]
35. The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies.
Atzpodien J; Kirchner H
Eur J Cancer; 1991; 27 Suppl 4():S88-91; discussion S92. PubMed ID: 1799491
[TBL] [Abstract][Full Text] [Related]
36. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Del Vecchio S; Riva E; Broccia C; Schiraldi O; Dianzani F
Clin Exp Immunol; 1994 Jul; 97(1):4-9. PubMed ID: 8033418
[TBL] [Abstract][Full Text] [Related]
37. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
[TBL] [Abstract][Full Text] [Related]
38. IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a.
Ross C; Engler CB; Sander B; Bendtzen K
J Interferon Cytokine Res; 2002 Apr; 22(4):421-6. PubMed ID: 12034024
[TBL] [Abstract][Full Text] [Related]
39. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients.
Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L
J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
